GlassScriptPhysician profile
Laura A Lee
NPI 1568545374
$4,778.06
in general payments reported to CMS, 2019-2025
35 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 81% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2022: $321 · 2023: $967 · 2024: $842 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,869.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $923.07 | 2019-2025 | Datroway, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $558.45 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Regeneron Healthcare Solutions, INC. | $374.30 | 2024-2025 | Libtayo |
| Lilly USA, LLC | $332.24 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $322.67 | 2023-2025 | Xpovio |
| Eisai INC. | $269.18 | 2023-2025 | |
| Vector Surgical, LLC | $200.00 | 2019 | |
| Merck Sharp & Dohme LLC | $191.60 | 2019-2025 | Welireg, Keytruda Qlex, Keytruda |
| Daiichi Sankyo INC. | $179.50 | 2025 | Datroway, Enhertu |
| Menarini Silicon Biosystems, INC. | $168.08 | 2023 | Cellsearch |
| Amgen INC. | $164.05 | 2023-2025 | Imdelltra (Amg757), Xgeva, Nplate |
| Telix Pharmaceuticals | $147.45 | 2022 | |
| Novocure INC. | $131.93 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Jazz Pharmaceuticals INC. | $119.35 | 2025 | |
| Glaxosmithkline, LLC. | $49.33 | 2025 | Zejula, Jemperli |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $48.38 | 2025 | |
| Rigel Pharmaceuticals, INC. | $44.43 | 2023-2024 | Rezlidhia, Tavalisse |
| Kyowa Kirin, INC. | $42.13 | 2023 | Poteligeo |
| Incyte Corporation | $41.40 | 2019-2025 | Jakafi |
| Blueprint Medicines Corporation | $40.66 | 2022-2024 | Ayvakit |
| Array Biopharma INC | $40.15 | 2025 | Mektovi, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2025 | Fruzaqla |
| Celgene Corporation | $38.54 | 2019 | |
| Genzyme Corporation | $38.10 | 2022-2023 | |
| Leica Microsystems INC. | $37.77 | 2019 | |
| Taiho Oncology, INC. | $32.92 | 2023 | |
| Pharmaessentia USA Corporation | $32.81 | 2024 | Besremi |
| Sobi, INC | $24.98 | 2023 | |
| Aveo Pharmaceuticals, INC. | $23.94 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.10 | 2019 | |
| Pfizer INC. | $22.83 | 2022 | |
| Deciphera Pharmaceuticals INC. | $22.51 | 2025 | Tgct, Qinlock |
| Cepheid | $18.73 | 2022 | |
| Emd Serono, INC. | $17.96 | 2024 | |
| Baxter Healthcare | $15.86 | 2025 | Seprafilm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.